Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 
ORIGINAL ARTICLE
Year : 2018  |  Volume : 31  |  Issue : 3  |  Page : 1094-1098

Evaluation of serum Midkine as a novel marker in hepatocellular carcinomas


1 Department of Clinical Pathology, Faculty of Medicine, National Liver Institute, Menoufia University, Shebin El-Kom, Menoufia, Egypt
2 Department of Clinical Pathology, National Liver Institute, Menoufia University, Shebin El-Kom, Menoufia, Egypt

Correspondence Address:
Doaa A Eisaa
Al-Amir Street, Berkit Elsabaa, Menoufia
Egypt
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/mmj.mmj_335_15

Rights and Permissions

Objectives To evaluate the clinical significance of serum Midkine (MDK) levels in the diagnosis of hepatocellular carcinoma (HCC) compared with alpha-fetoprotein (AFP). Background It was demonstrated that serum MDK levels are increased in cancer patients. So, it was suggested that MDK would likely be a novel marker for diagnosing tumors. In this study, we evaluated the significance of serum MDK levels in the diagnosis of HCC and early-stage HCC compared with AFP. Patients and methods The study was conducted on 90 patients who were divided into three groups: group I is the HCC group (n = 50), group II the liver cirrhosis group (n = 20), and group III is the control group (n = 20). Serum samples were obtained from all patients and were used to measure AFP and MDK levels. Receiver operating characteristic curves were drawn for both AFP and MDK in the diagnosis of HCC and early-stage HCC. Area under the curves (AUC) were calculated and were used to measure the sensitivity, specificity, and accuracy of both markers in the diagnosis of HCC and early HCC. Results AFP and MDK levels were increased in HCC over cirrhosis groups; and in HCC over control groups with a highly significant difference. MDK had the largest AUC in the diagnosis of both HCC (AUC = 1.00) and early-stage HCC (AUC = 0.829). In the diagnosis of HCC, serum MDK at a cutoff point of 0.62 ng/ml was 98.9% accurate compared with an accuracy of 73.3% for AFP at a cutoff point of 20.2 ng/ml. At a cutoff point of 0.92 ng/ml, serum MDK was 73.3% accurate in the diagnosis of early HCC compared with an accuracy of 65.6% for AFP at a cutoff point of 19.5 ng/ml. Conclusion Serum MDK could be a novel diagnostic tumor marker for the detection of HCC, particularly in patients at an early stage.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed246    
    Printed0    
    Emailed0    
    PDF Downloaded19    
    Comments [Add]    

Recommend this journal